2SEVENTY BIO INC (TSVT) Stock Analyst Ratings
NASDAQ:TSVT - Nasdaq - US9013841070 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 49% to TSVT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.1. This target is 2.2% above the current price.
TSVT was analyzed by 9 analysts. The buy percentage consensus is at 49. So analysts seem to be rather neutral about TSVT.
In the last month the buy percentage fell by 28 points. So the trust of analysts is decreasing.
TSVT was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-14 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-03-11 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-07-29 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-06-27 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-05-09 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-04-08 | Citigroup | Maintains | Buy -> Buy |
| 2024-03-18 | Wedbush | Reiterate | Neutral -> Neutral |
| 2024-01-31 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-01-31 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-11-20 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-10-30 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2023-10-12 | Citigroup | Initiate | Buy |
| 2023-09-13 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023-09-13 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2023-09-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2023-08-15 | Guggenheim | Maintains | Buy -> Buy |
| 2023-08-15 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-07-28 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-28 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2023-07-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-05-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-05-15 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-03-17 | Wedbush | Maintains | Outperform |
| 2023-01-24 | Morgan Stanley | Maintains | Overweight |
| 2023-01-20 | Goldman Sachs | Maintains | Buy |
| 2023-01-10 | SVB Leerink | Maintains | Outperform |
| 2022-11-08 | SVB Leerink | Maintains | Outperform |
| 2022-11-08 | Morgan Stanley | Maintains | Overweight |
| 2022-10-31 | Guggenheim | Initiate | Buy |
| 2022-08-15 | Morgan Stanley | Maintains | Overweight |